Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 9/2016

Open Access 01-09-2016 | Practical Application

Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial

Authors: Stéphane Verguet, Jane J. Kim, Dean T. Jamison

Published in: PharmacoEconomics | Issue 9/2016

Login to get access

Abstract

Health policy instruments such as the public financing of health technologies (e.g., new drugs, vaccines) entail consequences in multiple domains. Fundamentally, public health policies aim at increasing the uptake of effective and efficient interventions and at subsequently leading to better health benefits (e.g., premature mortality and morbidity averted). In addition, public health policies can provide non-health benefits in addition to the sole well-being of populations and beyond the health sector. For instance, public policies such as social and health insurance programs can prevent illness-related impoverishment and procure financial risk protection. Furthermore, public policies can improve the distribution of health in the population and promote the equalization of health among individuals. Extended cost-effectiveness analysis was developed to address health policy assessment, specifically to evaluate the health and financial consequences of public policies in four domains: (1) the health gains; (2) the financial risk protection benefits; (3) the total costs to the policy makers; and (4) the distributional benefits. Here, we present a tutorial that describes both the intent of extended cost-effectiveness analysis and its keys to allow easy implementation for health policy assessment.
Appendix
Available only for authorised users
Footnotes
1
Note that formula (3) may be generalized to include prevention.
 
Literature
1.
Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
2.
Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
3.
Jamison DT. Cost effectiveness analysis: concepts and applications. In Detels R, McEwen J, Beaglehole R, Tanaka H, editors. Oxford textbook of public health. Volume 2: the methods of public health. 5th ed. Oxford: Oxford University Press; 2009. p. 767–782.
4.
Kim JJ, Salomon JA, Weinstein MC, Goldie SJ. Packaging health services when resources are limited: the example of a cervical cancer screening visit. PLoS Med. 2006;3(11):e34.CrossRef
5.
Rheingans RD, Atherly D, Anderson J. Distributional impact of rotavirus vaccination in 25 GAVI countries: estimating disparities in benefits and cost-effectiveness. Vaccine. 2012;30(Suppl 1):A15–23.CrossRefPubMed
6.
World Health Organization. Making fair choices on the path to universal health coverage. Geneva: World Health Organization; 2014.
7.
Baltussen R, Niessen L. Priority setting of health interventions: the need for multi-criteria decision analysis. Cost Eff Resour Allocation. 2006;4:14.CrossRef
8.
Birch S, Gafni A. Cost-effectiveness/utility analyses: do current decisions lead us to where we want to be? J Health Econ. 1992;11:279–96.CrossRefPubMed
9.
Stinnett AA, Paltiel DA. Mathematical programming for the efficient allocation of health care resources. J Health Econ. 1996;15:641–53.CrossRefPubMed
10.
Bleichrodt H, Diecidue E, Quiggin J. Equity weights in the allocation of health care: the rank-dependent QALY model. J Health Econ. 2004;23:157–71.CrossRefPubMed
11.
Epstein D, Chalabi Z, Claxton K, Sculpher M. Efficiency, equity, and budgetary policies: informing decisions using mathematical programming. Med Decis Mak. 2007;27:128–37.CrossRef
12.
Verguet S. Efficient and equitable HIV prevention: a case study of male circumcision in South Africa. Cost Eff Resour Allocation. 2013;11:1.CrossRef
13.
Cookson R, Drummond M, Weatherly H. Explicit incorporation of equity considerations into economic evaluation of public health interventions. Health Econ Policy Law. 2009;4(2):231–45.CrossRefPubMed
14.
Asaria M, Griffin S, Cookson R, et al. Distributional cost-effectiveness analysis of health care programmes: a methodological study of the UK Bowel cancer screening programme. Health Econ. 2015;24(6):742–54.CrossRefPubMed
15.
Mauskopf JA, Paul JE, Grant DM, Stergachis A. The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics. 1998;13(3):277–88.CrossRefPubMed
16.
Marsh K, Lanitis T, Neasham D, Orfanos P, Caro J. Assessing the value of healthcare interventions using multi-criteria decision analysis: a review of the literature. PharmacoEconomics. 2014;32(4):345–65.CrossRefPubMed
17.
Murray CJL, Frenk J. A framework for assessing the performance of health systems. Bull World Health Org. 2000;78(6):717–31.PubMedPubMedCentral
18.
Webster C. The National Health Service: a political history. Toronto: Oxford University Press; 2002.
19.
Wagstaff A. Measuring financial protection in health. In: Smith PC, Mossialos E, Papanicolas I, Leatherman S, editors. In: Performance measurement for health system improvement. Cambridge: Cambridge University Press; 2010.
20.
21.
Marmot M, Wilkinson RG. Social determinants of health. 2nd ed. Oxford/New York: Oxford University Press; 2006.
22.
Olshansky SJ, Antonucci T, Berkman L, et al. Differences in life expectancy due to race and educational differences are widening, and many may not catch up. Health Aff. 2012;31(8):1803–13.CrossRef
23.
Murray CJL, Kulkarni SC, Michaud C, Tomijima N, Bulzacchelli MT, et al. Eight Americas: investigating mortality disparities across races, counties, and race-counties in the United States. PLoS Med. 2006;3(12):e545.CrossRefPubMedCentral
24.
Memirie ST, Verguet S, Norheim OF, Levin C, Johansson KA. Inequalities in utilization of maternal and child health services in Ethiopia: the role of primary health care. BMC Health Serv Res. 2016;16:51.CrossRefPubMedPubMedCentral
25.
Verguet S, Laxminarayan R, Jamison DT. Universal public finance of tuberculosis treatment in India: an extended cost-effectiveness analysis. Health Econ. 2015;24(3):318–32.CrossRefPubMed
26.
Watkins DA, Olson ZD, Verguet S, et al. Cardiovascular disease and impoverishment averted due to a salt reduction policy in South Africa: an extended cost-effectiveness analysis. Health Policy Plan. 2016;31(1):75–82.CrossRefPubMed
27.
28.
Verguet S, Olson ZD, Babigumira JB, et al. Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis. Lancet Glob Health. 2015;3:e288–96.CrossRefPubMed
29.
Smith PC. Incorporating financial protection into decision rules for publicly financed healthcare treatments. Health Econ. 2013;22:180–93.CrossRefPubMed
30.
McClellan M, Skinner J. The incidence of Medicare. J Public Econ. 2006;90:257–76.CrossRef
31.
Salem ABZ, Mount TD. A convenient descriptive model of income distribution: the gamma density. Econometrica. 1974;42(6):1115–27.CrossRef
32.
33.
Pratt JW. Risk aversion in the small and in the large. Econometrica. 1964;32(1):122–36.CrossRef
34.
Arrow KJ. Aspects of the theory of risk bearing. Helsinki: Academic Bookstores; 1965.
35.
Feldstein M, Gruber J. A major risk approach to health insurance reform. Tax Policy Econ. 1995;9:103–30.CrossRef
36.
Finkelstein A, McKnight R. What did Medicare do? The initial impact of Medicare on mortality and out of pocket medical spending. J Public Econ. 2008;92:1644–68.CrossRef
37.
Mitchell OS, Poterba JM, Warshawsky MJ, Brown JR. New evidence on the money’s worth of individual annuities. Am Econ Rev. 1999;89(5):1299–318.CrossRef
38.
Hubbard RG, Skinner J, Zeldes SP. Precautionary saving and social insurance. J Political Econ. 1995;103(2):360–99.CrossRef
39.
Scholz JK, Seshadri A, Khitatrakun S. Are Americans saving “optimally” for retirement? J Political Econ. 2006;114(4):607–43.CrossRef
40.
Engen EM, Gale WG, Uccello CE. The adequacy of household saving. Brook Pap Econ Act. 1999;2:65–187.CrossRef
41.
Brown JR, Finkelstein A. The interaction of public and private insurance: medicaid and the long-term care insurance market. Am Econ Rev. 2008;98(3):1083–102.CrossRef
42.
Keane MP, Wolpin KI. The effect of parental transfers and borrowing constraints on educational attainment. Int Econ Rev. 2001;42(4):1051–103.CrossRef
43.
44.
Rosenzweig MR, Wolpin KI. Credit market constraints, consumption smoothing, and the accumulation of durable production assets in low-income countries: investments in bullocks in India. J Political Econ. 1993;101(2):223–44.CrossRef
45.
Laibson DI, Repetto A, Tobacman J. Self-control and saving for retirement. Brook Pap Econ Act. 1998;1:91–172.CrossRef
46.
Cagetti M, de Nardi M. Entrepreneurship, frictions and wealth. J Political Econ. 2006;114(5):835–70.CrossRef
47.
Davis SJ, Kubler F, Willen P. Borrowing costs and the demand for equity over the life cycle. Rev Econ Stat. 2006;88(2):348–62.CrossRef
48.
Verguet S, Murphy SM, Anderson B, et al. Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis. Vaccine. 2013;31(42):4902–10.CrossRefPubMed
49.
World Health Organization. World Health Report 2010: health systems financing: the path to universal coverage. Geneva: World Health Organization; 2010.
50.
Husereau D, Drummond M, Petrou S, Carswell C, Moher D, et al. Consolidated health economic evaluation reporting standards (CHEERS): explanation and elaboration. A report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16:231–50.CrossRefPubMed
Metadata
Title
Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial
Authors
Stéphane Verguet
Jane J. Kim
Dean T. Jamison
Publication date
01-09-2016
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 9/2016
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-016-0414-z

Other articles of this Issue 9/2016

PharmacoEconomics 9/2016 Go to the issue

Original Research Article

Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland

Systematic Review

Use of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not Available

Review Article

The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence

Systematic Review

Cost Effectiveness of HPV Vaccination: A Systematic Review of Modelling Approaches

Original Research Article

Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting

Systematic Review

Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer